USP 795, 797, 800 Explained: What Every Compounding Pharmacy Partner Should Demonstrate

Why USP Standards Matter for Prescribers

When a physician writes a prescription to a compounding pharmacy, the quality of the dispensed product depends on the pharmacy’s internal systems. USP chapters are the standards that define what those systems should look like. Physicians don’t need to be pharmacy-operations experts, but understanding what USP 795, 797, and 800 cover allows meaningful due diligence on compounding partners.

This post is a clinician-focused explainer of the three most relevant chapters.

 

USP 795: Non-Sterile Compounding

USP Chapter 795 covers non-sterile compounding — the preparation of compounded medications that do not require sterile conditions. This includes oral capsules, topical creams, oral liquids, and other dosage forms administered through non-sterile routes.

Key areas USP 795 addresses:

• Pharmacy facility design and cleanliness requirements
• Personnel qualifications and training
• Component (ingredient) handling and documentation
• Equipment and utensil requirements
• Standard Operating Procedures (SOPs)
• Beyond-Use Date (BUD) determination for compounded preparations
• Quality control requirements
• Record-keeping

A pharmacy compounding topical peptide creams, oral bioregulator preparations, or similar non-sterile products should be operating under USP 795.

 

USP 797: Sterile Compounding

USP Chapter 797 covers sterile compounding — preparations for injection, ophthalmic use, or other sterile routes. For peptide practice, USP 797 is directly relevant because most peptide therapies are injected.

Key areas USP 797 addresses:

• ISO-classified cleanroom environments
• Air quality and particulate control
• Environmental monitoring
• Personnel training and competency testing
• Gowning and aseptic technique requirements
• Media fill testing
• Beyond-Use Date determination for sterile preparations
• Labeling and documentation
• Risk-level categorization (low, medium, high risk compounding)

The April 2023 update to USP 797 tightened requirements substantially. Pharmacies compounding sterile peptide preparations should demonstrate compliance with the current version of the chapter.

 

USP 800: Hazardous Drug Handling

USP Chapter 800 covers the handling of hazardous drugs in the compounding environment. Not every compounding pharmacy needs to apply USP 800 — it applies specifically to facilities handling hazardous drugs as classified by NIOSH.

Key areas USP 800 addresses:

• Hazardous drug identification and classification
• Receipt and storage protocols
• Compounding area requirements for hazardous drugs
• Personal protective equipment (PPE)
• Closed-system transfer devices (CSTDs) for chemotherapy-type compounds
• Deactivation, decontamination, and cleaning procedures
• Spill procedures
• Medical surveillance of personnel

For typical physician-directed peptide practice, USP 800 is less commonly directly relevant because the peptides being compounded are not on NIOSH hazardous drug lists. However, a pharmacy that compounds across categories — including chemotherapy or reproductive hormones — should demonstrate USP 800 compliance.

 

How to Evaluate Your Compounding Partner

Due diligence questions for a prospective or current compounding partner:

• Can the pharmacy document current USP 795 and 797 compliance?
• Is the pharmacy operating in accordance with the current (post-April 2023) USP 797?
• If the pharmacy handles hazardous drugs, is USP 800 compliance documented?
• What is the frequency of state board of pharmacy inspection?
• What is the inspection history?
• Does the pharmacy perform environmental monitoring?
• Can the pharmacy provide certificates of analysis for finished products?
• Are there analytical testing agreements with third-party laboratories?

Answers to these questions distinguish quality-demonstrated partners from those operating with less rigor.

 

Why Compliance Is Not Uniform Across the Industry

Not every business calling itself a “compounding pharmacy” operates at the same quality level. The compounding pharmacy market includes:

• Quality-demonstrated 503A facilities operating rigorously under USP standards
• Smaller pharmacies with variable systems
• Businesses operating at the margins of the regulatory framework

A compounding pharmacy operating under current USP standards with documented compliance and clean inspection history is qualitatively different from one that cannot demonstrate these features.

 

Key Takeaways

• USP 795 covers non-sterile compounding; USP 797 covers sterile (injectable) compounding; USP 800 covers hazardous drug handling.
• Most peptide compounding involves USP 797 directly, given the injectable delivery route of most peptides.
• The 2023 USP 797 revision tightened requirements; compounding partners should be on the current version.
• Due diligence on a compounding partner should include documented compliance verification.
• Quality varies across the industry; compliance with USP standards is a meaningful differentiator.

 

Frequently Asked Questions

What is USP 797?

A USP chapter establishing standards for sterile compounding — cleanroom design, aseptic technique, environmental monitoring, and related quality systems.

What is USP 795?

A USP chapter establishing standards for non-sterile compounding — topicals, orals, and other non-injectable preparations.

What is USP 800?

A USP chapter establishing standards for handling hazardous drugs in the compounding environment.

Do all compounding pharmacies follow USP?

They should. In practice, compliance is variable. Verifying your compounding partner’s current compliance is appropriate due diligence.

Contact Us